GLP-1 agonists: laryngeal side effects

A retrospective cohort study published in The Laryngoscope on 12 August 2026 found that GLP-1 receptor agonists raised the six-month risk of laryngeal symptoms in obese adults compared with matched controls, with cough showing the sharpest elevation^[1]. The analysis covered 617,296 patients on GLP-1 receptor agonists and more than 3.5 million controls drawn from the TriNetX United States Collaborative Network.

What the study measured and found

Shah and colleagues compared obese adults who received a GLP-1 receptor agonist at any point between January 2016 and December 2025 against a propensity-matched control group. The primary outcome was the six-month incidence of any laryngeal manifestation. The headline result: an odds ratio of 1.19 (95% CI 1.16 to 1.21; p < 0.0001) for any laryngeal symptom in the GLP-1 group^[1].

Breaking down the signal by symptom type, cough carried the highest odds ratio at 1.46 (p < 0.0001). Foreign body sensation in the throat came in at OR 1.41 (p < 0.001). Voice and resonance disorders reached OR 1.19 (p = 0.002)^[1]. The authors note that the absolute risk differences were small, but the scale of GLP-1 prescribing across the United States makes even a modest relative increase clinically relevant to otolaryngologists and prescribers.

Which agents drove the signal

Not all GLP-1 receptor agonists performed equally. Exenatide, liraglutide, semaglutide, dulaglutide, and lixisenatide each showed statistically significant associations with laryngeal symptoms^[1]. Albiglutide and tirzepatide (a dual GIP and GLP-1 receptor agonist) did not reach statistical significance, though the authors caution that smaller prescribing volumes in this dataset may limit the power to detect an effect for those agents.

Possible mechanisms behind laryngeal effects

The paper does not establish a causal mechanism, but two explanations are biologically plausible. First, GLP-1 receptors are expressed in the vagal nerve pathways that govern cough and sensory signalling in the larynx and upper airways. Activation of these receptors may lower the cough threshold, a pattern that mirrors the class-specific cough signal seen with ACE inhibitors through a different pathway. Second, the gastrointestinal slowing associated with GLP-1 receptor agonists may increase gastro-oesophageal reflux and laryngopharyngeal reflux, both well-established causes of chronic cough and voice change. A separate 2026 systematic review of GLP-1 pulmonary adverse events covering 19 studies noted that upper respiratory tract infections were the most frequently reported event class and called for moving the field from signal detection to causal inference^[2].

What this does not mean

This is a retrospective observational study. The TriNetX dataset is rich but cannot capture unmeasured confounders: patients prescribed GLP-1 receptor agonists may have higher rates of obesity-related reflux at baseline, may be more likely to present to healthcare providers and thus receive a laryngeal diagnosis, or may differ in other ways from the control population that propensity matching did not fully balance. The study also does not report symptom severity, duration, or whether voice and cough resolved on dose reduction or discontinuation.

On the benefit side of the upper-airway ledger, weight loss induced by GLP-1 receptor agonists reduces upper-airway fat deposition and improves obstructive sleep apnea. A 2026 case report in Obes Facts recorded an apnea-hypopnea index falling from 54.8 to 4.4 events per hour in a patient on tirzepatide over 12 months, attributing improvements to both weight reduction and direct effects on airway patency^[3]. The new laryngeal symptom data and the sleep apnea benefit literature are not in conflict; they describe different parts of the upper airway at different timescales.

What this means for patients and prescribers

If you develop a persistent cough, a sensation of something in the throat, or changes to your voice after starting a GLP-1 receptor agonist, these symptoms are worth raising with your prescriber. They are not listed prominently in current prescribing information for most agents in the class, but this study suggests they occur at a higher rate than in matched controls. Your clinician can assess whether reflux, a direct drug effect, or another cause is most likely and adjust management accordingly.

What we do not yet know

Several gaps remain. The mechanism driving laryngeal symptoms is unconfirmed. Whether the signal differs by dose (for example, whether the higher doses used for weight management show a stronger effect than the lower doses approved for glycaemic control) has not been reported. Long-term data on whether symptoms resolve with continued use are absent. And the study did not examine whether discontinuing the GLP-1 receptor agonist led to resolution, which would be the cleanest evidence for causality. Those questions will need prospective design to answer.